You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

Article info

Article menu

Download PDFPDF

Spondyloarthritis
Original research
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

Authors

  • Agathe Denis Service de Rhumatologie de Hautepierre, RESO, Centre de Référence des Maladies Autoimmunes Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, Strasbourg, France PubMed articlesGoogle scholar articles
  • Cédric Sztejkowski Service de Rhumatologie de Hautepierre, RESO, Centre de Référence des Maladies Autoimmunes Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, Strasbourg, France PubMed articlesGoogle scholar articles
  • Laurent Arnaud Service de Rhumatologie de Hautepierre, RESO, Centre de Référence des Maladies Autoimmunes Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, Strasbourg, France PubMed articlesGoogle scholar articles
  • Guillaume Becker Pôle Pharmacie-Pharmacologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France PubMed articlesGoogle scholar articles
  • Renaud Felten Service de Rhumatologie de Hautepierre, RESO, Centre de Référence des Maladies Autoimmunes Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, Strasbourg, FranceCentre d’Investigation Clinique, Inserm 1434, INSERM, Strasbourg, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Renaud Felten; renaud.felten{at}chru-strasbourg.fr
View Full Text

Citation

Denis A, Sztejkowski C, Arnaud L, et al
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
RMD Open 2023;9:e003279. doi: 10.1136/rmdopen-2023-003279

Publication history

  • Received May 2, 2023
  • Accepted July 15, 2023
  • First published July 28, 2023.
Online issue publication 
July 28, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.